WASHINGTON - The final results of a clinical trial show convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, the National Institutes of Health announced Wednesday.Last year, the U.S.
Food and Drug Administration issued an Emergency Use Authorization for convalescent plasma in hospitalized patients with COVID-19.